Wegovy is generally available again since the FDA declared the shortage ended on February 21, 2025. However, certain lower doses (0.25 mg, 0.5 mg, and 1 mg) still have limited availability, and demand continues to exceed supply. Novo Nordisk, the manufacturer, is managing shipments to prioritize existing patients, and some supply constraints may persist. The full normalization of supply is ongoing but the shortage officially ended early in 2025.
Additionally, new distribution partnerships, such as with WeightWatchers starting July 2025, aim to improve access to Wegovy. Generic versions are not available yet, with earliest potential generics expected around December 2031.
In summary, Wegovy is available again but with some limits on lower doses and ongoing supply management for patient access.
